RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B LIGAND (RANKL) AND OSTEOPROTEGERIN (OPG) IN RADICULAR CYSTS, DENTIGEROUS CYSTS AND HEALTHY VOLUNTEERS

被引:0
|
作者
Pechalova, Petia F. [1 ]
Poriazova, Elena G. [2 ]
Pavlov, Nikolai V. [3 ]
Gospodinov, Dimitar L. [1 ]
机构
[1] Med Univ Plovdiv, Dept Oral Surg, 3 Hristo Botev Blvd, Plovdiv 4003, Bulgaria
[2] Med Univ Plovdiv, Dept Pathol, 15A Vasil Aprilov St, Plovdiv 4002, Bulgaria
[3] 15A Lozarska St, Plovdiv 4003, Bulgaria
来源
关键词
OPG; RANKL; radicular cyst; dentigerous cyst; OSTEOCLASTOGENESIS-INHIBITORY FACTOR; DIFFERENTIATION FACTOR; APICAL PERIODONTITIS; BONE; EXPRESSION; GRANULOMAS; CYTOKINE; DISEASE; LESIONS;
D O I
暂无
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Radicular and dentigerous cysts are the two most common histological types of jaw cysts. Their growth is related to bone loss. The process of bone destruction takes place under the action of cytokines receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG). The objective of this study is to examine how the concentration of RANKL and OPG is changing in patients with both types of cysts and healthy volunteers. The study includes 15 patients with radicular cysts, 15 with dentigerous cysts and 30 healthy control volunteers. The study investigated serum concentration of sRANKL and OPG in patients and volunteers, as well as the expression of RANKL and OPG in the epithelial sac of the cysts. The results showed elevated sRANKL levels in patients with cysts compared to the healthy volunteers. Serum OPG levels in patients with radicular cysts were higher compared to those of the control group. RANKL in the epithelial sac of dentigerous cysts was higher compared to the epithelial sac of radicular cysts. To precisely specify the role of cytokines RANKL and OPG in the process of bone destruction in radicular and dentigerous cysts, further studies shall be performed.
引用
收藏
页码:385 / 392
页数:10
相关论文
共 50 条
  • [41] Serum level of receptor activator of nuclear factor kappa-B ligand in patients with psoriasis
    Amin, Tarek E.
    ElFar, Nashwa N.
    Ghaly, Nahla R.
    Hekal, Mona M.
    Hassan, Azza M.
    Elsaadany, Hanan M.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2016, 55 (05) : E227 - E233
  • [42] Receptor activator of nuclear factor kappa-B ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis
    Burska, A. N.
    El-Jawhari, J. J.
    Wu, J.
    Wakefield, R. J.
    Marzo-Ortega, H.
    Conaghan, P. G.
    Emery, P.
    Ponchel, F.
    Freeston, J. E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (03) : 456 - 462
  • [43] Increases in bone turnover and the receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio during high prolactin exposure
    Krishnamra, N.
    Seriwatanachai, D.
    Thongchote, K.
    Suthiphongchai, T.
    Charoenphandhu, N.
    BONE, 2007, 40 (06) : S210 - S211
  • [44] Serum Osteoprotegrin (OPG) and Receptor Activator of Nuclear Factor κB (RANKL) in Healthy Children and Adolescents
    Wasilewska, A.
    Rybi-Szuminska, A. A.
    Zoch-Zwierz, W.
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2009, 22 (12): : 1099 - 1104
  • [45] Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours
    Van Poznak, C
    Cross, SS
    Saggese, M
    Hudis, C
    Panageas, KS
    Norton, L
    Coleman, RE
    Holen, I
    JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (01) : 56 - 63
  • [46] OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF THE NUCLEAR FACTOR KAPPA B LIGAND (RANKL) IN HEALTHY PUBERTAL GIRLS- RELATIONSHIPS WITH PHYSICAL GROWTH AND CLASSICAL BONE TURNOVER MARKERS
    Kulik-rechberger, B.
    Kozlowska, M.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 75 (01): : 63 - 70
  • [47] Expression Profile of Receptor Activator of Nuclear-κB (RANK), RANK Ligand (RANKL) and Osteoprotegerin (OPG) in Breast Cancer
    Owen, Sioned
    Ye, Lin
    Sanders, Andrew J.
    Mason, Malcolm D.
    Jiang, Wen G.
    ANTICANCER RESEARCH, 2013, 33 (01) : 199 - 206
  • [48] Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma
    Panagiotidis, Ioannis
    Christoulas, Dimitrios
    Terpos, Evangelos
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (24)
  • [49] Receptor Activator of Nuclear Factor kappa-B Ligand is Not Regulated During Chronic Osteomyelitis in Pigs
    Luthje, F. L.
    Skovgaard, K.
    Jensen, H. E.
    Blirup-Plum, S. A.
    Henriksen, N. L.
    Aalbaek, B.
    Jensen, L. K.
    JOURNAL OF COMPARATIVE PATHOLOGY, 2020, 179 : 7 - 24
  • [50] Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
    Boman, Antonia
    Kokkonen, Heidi
    Arlestig, Lisbeth
    Berglin, Ewa
    Rantapaa-Dahlqvist, Solbritt
    CLINICAL RHEUMATOLOGY, 2017, 36 (05) : 1005 - 1012